2. Search Result
Search Result
Results for "

morphological changes

" in MedChemExpress (MCE) Product Catalog:

69

Inhibitors & Agonists

1

Fluorescent Dye

3

Biochemical Assay Reagents

5

Peptides

1

MCE Kits

11

Natural
Products

9

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0113
    Omeprazole
    5+ Cited Publications

    H 16868

    		 Na+/K+ ATPase Proton Pump Bacterial Cytochrome P450 Apoptosis Autophagy Atg8/LC3 TNF Receptor Interleukin Related Infection Neurological Disease Inflammation/Immunology Cancer
    Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole
  • HY-W020780
    mPEG5000-Mal

    mPEG5000-Maleimide

    		 Biochemical Assay Reagents Cancer
    mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses .
    mPEG5000-Mal
  • HY-B0113A
    Omeprazole sodium
    5+ Cited Publications

    H 16868 sodium

    		 Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Inflammation/Immunology
    Omeprazole (H 16868) sodium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
    Omeprazole sodium
  • HY-134508
    C24-Ceramide

    		mTOR Neurological Disease Cancer
    C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .
    C24-Ceramide
  • HY-W356116
    C6 NBD Ceramide

    Nbd-ceramide

    		 Fluorescent Dye Others
    C6 NBD Ceramide is a Golgi apparatus fluorescent probe with cell membrane permeability. C6 NBD Ceramide can be used for fast and convenient green fluorescent labeling of Golgi in living and fixed cells, and can be used to observe changes in Golgi morphology in living cells (Ex=466 nm, Em=536 nm). C6-NBD-ceramide is metabolized to fluorescent sphingomyelin and glucosylceramide, can be used for the study of sphingolipid transport and metabolic mechanism .
    C6 NBD Ceramide
  • HY-174374
    Topobexin

    		Topoisomerase Cardiovascular Disease
    Topobexin is a TOP2B-selective inhibitor with IC50 values of 0.19 μM and 4.8 μM for TOP2B and TOP2A (DNA decatenation assay). Topobexin binds to non-homologous residues in the obex pocket and targets the ATPase domain of TOP2B. Topobexin prevents anthracycline-induced DNA double-strand break formation, apoptotic signaling mediated by caspase 3/7, 8 and 9, cardiomyocyte morphological changes, mitochondrial depolarization/loss, left ventricular systolic dysfunction, extracellular matrix remodeling, fibrotic alterations, and increases in plasma cardiac troponin T and BNP. Topobexin does not impair the antiproliferative effects of anthracyclines in cancer cells, exhibits no intrinsic cytotoxicity in cardiomyocytes, and is well tolerated in rabbits. Topobexin can be used in studies related to anthracycline-induced cardiotoxicity .
    Topobexin
  • HY-P10304
    Cyclo(Arg-Pro)

    Cyclo(Pro-Arg)

    		 Fungal Others
    Cyclo(Arg-Pro) (Cyclo(Pro-Arg)) is an inhibitor for chitinase. Cyclo(Arg-Pro) inhibits cell separation of Saccharomyces cerevisiae, without affecting its growth. Cyclo(Arg-Pro) inhibits the morphological change of Candida albicans from yeast form to filamentous form .
    Cyclo(Arg-Pro)
  • HY-126356
    1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

    		Liposome Cardiovascular Disease
    1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .
    1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
  • HY-W035091
    Tetrachloroauric acid
    1 Publications Verification

    		 Biochemical Assay Reagents Cardiovascular Disease Neurological Disease
    Tetrachloroauric acid is an Au (III) compound and bilayer disruptor that can be used to damage red blood cells. Tetrachloroauric acid specifically disrupts the bilayer structure of representative phospholipids (dimyristoylphosphatidylcholine and dimyristoylphosphatidylethanolamine) in human red blood cell membranes, and induces morphological changes in intact human red blood cells. Tetrachloroauric acid causes downregulation of MT I-II and GFAP expression in the mouse brain following chronic treatment. Tetrachloroauric acid is being used in studies related to neurotoxicity and hematotoxicity, including analyses of human red blood cells and molecular models of red blood cell membranes, as well as immunohistochemical evaluation of the mouse brain .
    Tetrachloroauric acid
  • HY-N2438
    Methylophiopogonanone B
    2 Publications Verification

    		 Ras Microtubule/Tubulin Cancer
    Methylophiopogonanone B is a homoisoflavonoid compound. Methylophiopogonanone B can be isolated from O. japonicus root. Methylophiopogonanone B promotes Rho activation and Tubulin depolymerization. Methylophiopogonanone B significantly increases GTP-Rho, but not GTP-Rac or GTP-CDC42. Methylophiopogonanone B induces cell morphological change via melanocyte dendrite retraction and stress fiber formation. Methylophiopogonanone B exhibits strong antioxidant activity. Methylophiopogonanone B can be used in the research of cervical cancer .
    Methylophiopogonanone B
  • HY-N6801
    Nivalenol

    		Caspase Apoptosis Bcl-2 Family Infection Inflammation/Immunology Cancer
    Nivalenol, a trichothecene mycotoxin that can be produced by Fusarium graminearum, is a fungal metabolite present in agricultural product. Nivalenol modulates apoptotic pathway, cell cycle regulation, Bax, ERK, caspase-3, and poly-ADP-ribose synthase activity in macrophages. Nivalenol inhibits ribosomal peptidyltransferase site, protein synthesis, DNA synthesis, and cell proliferation. Nivalenol induces late-stage apoptotic morphological changes, reduces cellular metabolism, and decreases cell proliferation in erythroleukemia cells. Nivalenol induces lymphocyte apoptosis in murine thymus, spleen, and Peyer's patches. Nivalenol can be used for the research of erythroleukemia .
    Nivalenol
  • HY-137341
    SK-3-91

    		PROTACs YTHDF Cancer
    SK-3-91 is a PROTAC-type multi-kinase degrader that can jointly induce the degradation of the largest number of unique kinases (more than 125 unique kinases). SK-3-91 induces protein degradation through the ubiquitin biotinylation (E-STUB) pathway. SK-3-91 degrades YTHDF2. SK-3-91 inhibits cell proliferation and induces morphological changes. (Pink: TAE648 ligand (HY-169396); Blue: E3 ligase ligand (HY-131717); Black: Linker (HY-140819). The E3 ligase ligand and linker can form a conjugate (HY-169397)) .
    SK-3-91
  • HY-NP163A
    Wheat germ agglutinin-AF488

    WGA-AF488

    		 Fluorescent Dye Cancer
    Wheat germ agglutinin-AF488 (WGA-AF488) is a cell membrane-specific staining agent prepared by conjugating wheat germ agglutinin with the Alexa Fluor 488 (HY-D1304) fluorescent dye, and it binds to cell surface glycoproteins with high affinity. Wheat germ agglutinin-AF488 is applied in fluorescence microscopy and confocal imaging techniques, and it can clearly label the membrane structures of various cells including breast cancer cells, enabling high-resolution visual observation. Wheat germ agglutinin-AF488 is used in studies of breast cancer and triple-negative breast cancer to observe cell morphology and membrane dynamic changes .
    Wheat germ agglutinin-AF488
  • HY-B0113R
    Omeprazole (Standard)

    H 16868 (Standard)

    		 Reference Standards Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole (Standard)
  • HY-B0113S
    Omeprazole-d3
    1 Publications Verification

    H 16868-d3

    		 Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole-d3 (H 16868-d3) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole-d3
  • HY-123635
    Nybomycin

    		Antibiotic Bacterial Infection
    Nybomycin, an antibiotic, exhibits antiphage and antibacterial properties. Nybomycin binds to DNA and induces a unique morphological change to mycobacterial bacilli leading the bacterial cell death .
    Nybomycin
  • HY-B1740
    Pregnenolone acetate

    		Microtubule/Tubulin Neurological Disease
    Pregnenolone acetate (compound #43), a nonmetabolized Pregnenolone (HY-B0151) analog, can promote neurite extension and induce a change in growth cone morphology in primary cultures of cerebellar granule neurons. Pregnenolone acetate, a neurosteroid, increases microtubule polymerization. Pregnenolone acetate has the potential for neurodevelopmental diseases research .
    Pregnenolone acetate
  • HY-163459
    HWY-289

    		Fungal Infection
    HWY-289 is a semisynthetic protoberberine derivative, has broad-spectrum and potent activities against phytopathogenic fungi, particularly Botrytis cinerea (EC50 = 1.34 μg/mL). HWY-289 changes the morphology of the mycelium and the internal structure of cells. HWY-289 reduces ATP content, ATPase activities, and key enzyme activities in the TCA cycle .
    HWY-289
  • HY-150187
    20:4 Lyso PI

    		GPR55 ERK ROCK Calcium Channel Neurological Disease
    20:4 Lyso PI acts as an activator of GPR55 and RhoA. 20:4 Lyso PI activates the GPR55-RhoA-ROCK pathway, thereby inducing morphological changes, cytoskeleton assembly, cell rounding and stress fiber formation. 20:4 Lyso PI can be used in research related to diseases such as those of the nervous system .
    20:4 Lyso PI
  • HY-109546
    Omeprazole magnesium

    		Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (H 16868) magnesium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium aslo has neuroprotective and antibacterial effects .
    Omeprazole magnesium
  • HY-B0113S3
    Omeprazole-13C,d3

    H 16868-13C,d3

    		 Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole- 13C,d3 is a 13C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole-13C,d3
  • HY-111423
    BDP8900

    		Cdc42-binding kinase Cancer
    BDP8900 is a potent and selective inhibitor of myotonic dystrophy-related Cdc42-binding kinases (MRCKα and MRCKβ). BDP8900 reduces substrate phosphorylation, leading to morphological changes, motility inhibition and invasiveness of cancer cells .
    BDP8900
  • HY-N6801S
    Nivalenol-13C15

    		Isotope-Labeled Compounds Caspase Apoptosis Bcl-2 Family Infection Inflammation/Immunology Cancer
    Nivalenol- 13C15 is the 13C labeled Nivalenol (HY-N6801) . Nivalenol, a trichothecene mycotoxin that can be produced by Fusarium graminearum, is a fungal metabolite present in agricultural product. Nivalenol modulates apoptotic pathway, cell cycle regulation, Bax, ERK, caspase-3, and poly-ADP-ribose synthase activity in macrophages. Nivalenol inhibits ribosomal peptidyltransferase site, protein synthesis, DNA synthesis, and cell proliferation. Nivalenol induces late-stage apoptotic morphological changes, reduces cellular metabolism, and decreases cell proliferation in erythroleukemia cells. Nivalenol induces lymphocyte apoptosis in murine thymus, spleen, and Peyer's patches. Nivalenol can be used for the research of erythroleukemia.
    Nivalenol-13C15
  • HY-N3765
    Diosbulbin D

    		Apoptosis Metabolic Disease
    Diosbulbin D is a potential hepatotoxic compound that can be isolated from Dioscorea bulbifera L.. Diosbulbin D induces apoptosis in L-02 cells .
    Diosbulbin D
  • HY-113091
    DL-α-Tocotrienol

    		Apoptosis Neurological Disease
    Alpha-Tocotrienol is a vitamin E analog with anti-apoptotic neuroprotective action and antioxidant properties. Alpha-Tocotrienol prevents oxidative stress-independent apoptotic cell death, DNA cleavage, and nuclear morphological changes .
    DL-α-Tocotrienol
  • HY-W040176
    N-PTyrosine PA ammonium

    N-Palmitoyl-tyrosine phosphoric acid ammonium

    		 LPL Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a lysophosphatidic acid (LPA) receptor modulator, which exhibits weak inhibitory activity against LPA1 and partial agonist properties towards LPA5. N-PTyrosine PA ammonium inhibits the activation of LPA receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke) .
    N-PTyrosine PA ammonium
  • HY-115507
    NMac1

    		AMPK mTOR ERK Oxidative Phosphorylation Reactive Oxygen Species (ROS) Ras Cancer
    NMac1 is an orally active Nm23/NDPK activator. NMac1 directly binds to Nm23-H1 and activates the NDPK activity of recombinant Nm23-H1 with an EC50 of 10.7 uM. NMac1 induces AMPK activation and inhibits mTOR and ERK, leading to mitochondrial OXPHOS dysregulation and suppressing mitochondrial ROS production, which in turn induces mitochondrial dysfunction in MDA-MB-231 cells. NMac1 inhibits Complex I activity and suppresses changes in morphology and actin cytoskeleton organization following Rac1 activation in MDA-MB-231 cells. NMac1 inhibits tumor invasion, migration and metastasis. NMac1 is useful for studying metastatic tumors, such as breast cancer. NMac1 can be isolated from the ginger cassumunar Roxb .
    NMac1
  • HY-145814
    HSP90-IN-9

    		HSP Fungal Infection
    HSP90-IN-9 is a potent and selective HSP90 inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2) .
    HSP90-IN-9
  • HY-124021
    Benzyl 2-naphthyl ether

    		Aryl Hydrocarbon Receptor Others
    Benzyl 2-naphthyl ether is a compound mentioned in the study of the effects of aromatic sensitizers on zebrafish embryos. It can cause morphological abnormalities and changes in gene expression in zebrafish embryos. Its toxicity mechanism is partly related to AHR, and there may be other mechanisms independent of AHR.
    Benzyl 2-naphthyl ether
  • HY-160998
    YM-344031

    		CCR Inflammation/Immunology
    YM-344031 is an orally active antagonist for CCR3. YM-344031 inhibits binding of Eotaxin-1 and RANTES to CCR3, with IC50 of 3.0 and 16.3 nM. YM-344031 inhibits ligand-induced rise in intracellular Ca [2+] and the ligand-induced chemotaxis. YM-344031 inhibits eotaxin-1-induced changes in eosinophil morphology in macaques blood, and prevents allergic skin reactions in a mouse allergy model .
    YM-344031
  • HY-U00449A
    AGN 193109 sodium

    		RAR/RXR Cancer
    AGN 193109 sodium is the sodium salt form of AGN 193109 (HY-U00449). AGN 193109 sodium is the pan antagonist for retinoic acid receptor (RAR), with Kd of 2, 2 and 3 nM, for RARα, RARβ and RARγ, respectively. AGN 193109 sodium reverses TTNPB-induced morphology changes and all-trans retinoic acid (tRA)/9-cis RA/13-cis RA-induced proliferation suppression in ECE16-1 cell. AGN 193109 sodium is the antidote for retinoic acidosis, that ameliorates the skin and mucosal toxicity .
    AGN 193109 sodium
  • HY-N6801R
    Nivalenol (Standard)

    		Reference Standards Caspase Apoptosis Bcl-2 Family Infection Inflammation/Immunology Cancer
    Nivalenol (Standard) is the analytical standard of Nivalenol (HY-N6801). This product is intended for research and analytical applications. Nivalenol, a trichothecene mycotoxin that can be produced by Fusarium graminearum, is a fungal metabolite present in agricultural product. Nivalenol modulates apoptotic pathway, cell cycle regulation, Bax, ERK, caspase-3, and poly-ADP-ribose synthase activity in macrophages. Nivalenol inhibits ribosomal peptidyltransferase site, protein synthesis, DNA synthesis, and cell proliferation. Nivalenol induces late-stage apoptotic morphological changes, reduces cellular metabolism, and decreases cell proliferation in erythroleukemia cells. Nivalenol induces lymphocyte apoptosis in murine thymus, spleen, and Peyer's patches. Nivalenol can be used for the research of erythroleukemia.
    Nivalenol (Standard)
  • HY-P10371
    PKHB1

    txCD47

    		 Reactive Oxygen Species (ROS) Thrombopoietin Receptor Mitochondrial Metabolism HSP HSV CD47 Infection Inflammation/Immunology Cancer
    PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8 + T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia .
    PKHB1
  • HY-133608
    4,6-Dichloroguaiacol

    		DNA/RNA Synthesis Inflammation/Immunology
    4,6-Dichloroguaiacol induces biochemical and morphological changes in human peripheral blood lymphocytes in vitro .
    4,6-Dichloroguaiacol
  • HY-P11021
    ToAP2

    		Fungal Antibiotic Infection
    ToAP2 is a potent antimicrobial peptide. ToAP2 affects C. albicans membrane permeability and produces changes in fungal cell morphology .
    ToAP2
  • HY-P11021A
    ToAP2 TFA

    		Fungal Antibiotic Infection
    ToAP2 TFA is a potent antimicrobial peptide. ToAP2 TFA affects C. albicans membrane permeability and produces changes in fungal cell morphology .
    ToAP2 TFA
  • HY-111190
    Thiotropocin

    		Antibiotic Bacterial Infection
    Thiotropocin is a tropothione Antibiotic with antibacterial activities against Gram-positive and Gram-negative bacteria, some phytopathogens and mycoplasma. Thiotropocin causes morphological changes of Proteus mirabilis and Escherichia coli .
    Thiotropocin
  • HY-120883
    Rhizopodin

    		Others Infection
    Rhizopodin is a new cytostatic compound isolated from the culture fluid of the slime mold Myxococcus stipitatus. Rhizopodin inhibits the growth of various animal cell cultures without killing the cells, with an ID50 value of 12 to 30 ng/ml, depending on the cell line. In particular, fibroblast-like cells show typical morphological changes, with cells becoming larger and forming long branched reticular extensions within hours, and these morphological changes are irreversible. Rhizopodin inhibits bleb formation in K-562 cells, possibly through interaction with protein phosphorylation.
    Rhizopodin
  • HY-155769
    Antimicrobial agent-24

    		Fungal Infection
    Antimicrobial agent-24 (compound E8) is a hydrazide compound with excellent and broad-spectrum fungicidal activities. Antimicrobial agent-24 affects the normal function of the plasma membrane, further generating changes in the morphology and subcellular structure of mycelia .
    Antimicrobial agent-24
  • HY-108553
    Dihydroeponemycin

    		Proteasome Apoptosis Cancer
    Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis .
    Dihydroeponemycin
  • HY-W721681
    Dehydro nicardipine

    		Amyloid-β Neurological Disease
    Dehydro nicardipine is a dihydropyridine metabolite of Nicardipine (HY-12515) and belongs to the dihydropyridine class of compounds. Dehydro nicardipine can selectively inhibit the aggregation of Aβ monomers, specifically regulate the extension and binding of Aβ soluble aggregates, change the morphology of Aβ aggregates, and inhibit the growth of aggregate length. Dehydro nicardipine can be used in the study of Alzheimer's disease (AD) .
    Dehydro nicardipine
  • HY-178781
    Antibacterial agent 297

    		Bacterial Infection
    Antibacterial agent 297 (Compound A40), an antibacterial agent, is a Lsrk inhibitor (IC50: 0.40 μM; KD: 3.79 μM). Antibacterial agent 297 inhibits biofilm formation and bacterial motility and changes biofilm morphology through AI-2 QS inhibition rather than direct antibacterial effects. Antibacterial agent 297 has favorable oral PK properties .
    Antibacterial agent 297
  • HY-172259
    Toyaburgine

    		PI3K Akt mTOR Cancer
    Toyaburgine is a unique isoquinoline compound that exhibits anti-tumor activity. It packs a punch by disrupting the PI3K/AKT/mTOR signaling pathway, causing significant morphological changes and cell death in MIA PaCa-2 cells. On top of that, it puts the brakes on cell migration and colony formation. This compound is showing a lot of promise in the realm of pancreatic cancer research .
    Toyaburgine
  • HY-168260
    CQ-Mito

    		Apoptosis Ferroptosis MMP Cancer
    CQ-Mito is a Coumarin-Quinazolinone (CQ)-based derivative that targets mitochondria and exhibits profound phototherapeutic performances with an Phototoxic Index (PI) value of 167. CQ-Mito causes cell death by both apoptosis and ferroptosis. CQ-Mito mediates mitochondrial dysfunction, including mitochondrial morphology changed and the loss of MMP. CQ-Mito can efficiently inhibit the tumor growth in organoid tumor models .
    CQ-Mito
  • HY-176413
    SDH-IN-27

    		Fungal Infection
    SDH-IN-27 (Compound Q18) is a succinate dehydrogenase inhibitor (SDHI) (IC50: 9.7 mg/L). SDH-IN-27 induces mycelial morphology changes and lipid peroxidation, and exhibits antifungal activity against C. camelliae (EC50: 6.0 mg/L). SDH-IN-27 is an ergosterol biosynthesis inhibitor (EBI) that binds to the active site of CYP51, ultimately leading to cell death of pathogenic fungi .
    SDH-IN-27
  • HY-168720
    Apoptosis inducer 32

    		Apoptosis Cancer
    Apoptosis inducer 32 (Compound 7g) is an apoptosis inducer with a KD of 42 μM, showing anti-tumor activity. Apoptosis inducer 32 caused significant cellular morphological changes in MDA-MB-231 cells, including membrane bubbling, nuclear fragmentation, and apoptotic body formation. The IC50 of Apoptosis inducer 32 in MCF-7, MDA-MB-231, and HEK cells is 4.77, 6.56 and 337.8 μM respectively .
    Apoptosis inducer 32
  • HY-156348
    MAO-B-IN-26

    		Monoamine Oxidase Autophagy Apoptosis Cholinesterase (ChE) Neurological Disease
    MAO-B-IN-26 (Compound IC9) is a MAO-B and acetylcholinesterase inhibitor. MAO-B-IN-26 protects SH?SY5Y cells against Aβ induced cytotoxicity, morphological changes, ROS generation and membrane damage. MAO-B-IN-26 also inhibits Aβ induced autophagy and apoptosis. MAO-B-IN-26 can be used as a neuroprotective agent against Alzheimer’s disease .
    MAO-B-IN-26
  • HY-B0113AR
    Omeprazole sodium (Standard)

    H 16868 sodium (Standard)

    		 Reference Standards Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (sodium) (Standard) is the analytical standard of Omeprazole (sodium). This product is intended for research and analytical applications. Omeprazole sodium (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
    Omeprazole sodium (Standard)
  • HY-B0113S4
    Omeprazole-d3 sodium

    H 16868-d3 sodium

    		 Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole-d3 sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole sodium (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
    Omeprazole-d3 sodium
  • HY-173052
    SLW131

    		CXCR Inflammation/Immunology
    SLW131 (Compound 10) is the antagonist for CCR7 with a good affinity of Ki of 9.85 nM. SLW131 inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM, inhibits β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 inhibits CCL19-induced cell morphological changes in primary BMDCs, and CCR7-mediated migration in mouse CD4+ T cell .
    SLW131

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: